Clinical Trial Update: Psilocybin for Treatment-Resistant Depression in Autism [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating psilocybin for treatment-resistant depression in individuals with autism spectrum disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Treatment-resistant Depression

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Centre for Addiction and Mental Health | Conditions: Treatment Resistant Depression, Autism Spectrum Disorder | Phase 1 | Status: RECRUITING